- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07223203
TRITON-PN: Studio per valutare l'efficacia e la sicurezza di Nucresiran in pazienti con amiloidosi da transtiretina ereditaria con polineuropatia (TRITON-PN)
TRITON-PN: Studio di Fase 3, globale, randomizzato, in aperto per valutare l'efficacia e la sicurezza di Nucresiran in pazienti con amiloidosi mediata da transtiretina ereditaria con polineuropatia (hATTR-PN)
The purpose of this study is to:
- Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed
- Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels
Panoramica dello studio
Stato
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 3
Contatti e Sedi
Contatto studio
- Nome: Clinical Trial Information Line
- Numero di telefono: 1-877-ALNYLAM
- Email: clinicaltrials@alnylam.com
Backup dei contatti dello studio
- Nome: Clinical Trial Information Line
- Numero di telefono: 1-877-256-9526
- Email: clinicaltrials@alnylam.com
Luoghi di studio
-
-
-
Belgrano, Argentina, C1428AQK
- Reclutamento
- Clinical Trial Site
-
Rosario, Argentina, CP2000
- Reclutamento
- Clinical Trial Site
-
-
-
-
-
Darlinghurst, Australia, 2010
- Reclutamento
- Clinical Trial Site
-
Woolloongabba, Australia, 4102
- Reclutamento
- Clinical Trial Site
-
-
-
-
-
Ribeirão Preto, Brasile, 14051-140
- Reclutamento
- Clinical Trial Site
-
Rio de Janeiro, Brasile, 22640-100
- Reclutamento
- Clinical Trial Site
-
Rio de Janeiro, Brasile, 22775-001
- Reclutamento
- Clinical Trial Site
-
Salvador, Brasile, 40290-000
- Reclutamento
- Clinical Trial Site
-
São Paulo, Brasile, 04038-002
- Reclutamento
- Clinical Trial Site
-
-
-
-
-
Vancouver, Canada, V5Z 1M9
- Reclutamento
- Clinical Trial Site
-
-
-
-
-
Égkomi, Cipro, 2371
- Reclutamento
- Clinical Trial Site
-
-
-
-
-
Seoul, Corea del Sud, 06351
- Reclutamento
- Clinical Trial Site
-
Seoul, Corea del Sud, 05030
- Reclutamento
- Clinical Trial Site
-
-
-
-
-
Créteil, Francia, 94000
- Reclutamento
- Clinical Trial Site
-
Le Kremlin-Bicêtre, Francia, 94270
- Reclutamento
- Clinical Trial Site
-
Marseille, Francia, 13005
- Reclutamento
- Clinical Trial Site
-
-
-
-
-
Berlin, Germania, 10117
- Reclutamento
- Clinical Trial Site
-
Heidelberg, Germania, 69120
- Reclutamento
- Clinical Trial Site
-
Münster, Germania, 48149
- Reclutamento
- Clinical Trial Site
-
-
-
-
-
Bunkyo C, Giappone, 113-8519
- Reclutamento
- Clinical Trial Site
-
Kumamoto, Giappone, 860-8556
- Reclutamento
- Clinical Trial Site
-
Matsumoto-shi, Giappone, 390-8621
- Reclutamento
- Clinical Trial Site
-
Suita, Giappone, 565-0871
- Reclutamento
- Clinical Trial Site
-
-
-
-
-
Athens, Grecia, 115 28
- Reclutamento
- Clinical Trial Site
-
Heraklion, Grecia, 715 00
- Reclutamento
- Clinical Trial Site
-
-
-
-
-
Dublin, Irlanda, D24 NR0A
- Reclutamento
- Clinical Trial Site
-
-
-
-
-
Florence, Italia, 50134
- Reclutamento
- Clinical Trial Site
-
Milan, Italia, 20133
- Reclutamento
- Clinical Trial Site
-
Padova, Italia, 35128
- Reclutamento
- Clinical Trial Site
-
Pavia, Italia, 27100
- Reclutamento
- Clinical Trial Site
-
Roma, Italia, 00168
- Reclutamento
- Clinical Trial Site
-
-
-
-
-
Kuala Lumpur, Malaysia, 59100
- Reclutamento
- Clinical Trial Site
-
-
-
-
-
Guadalajara, Messico, 44670
- Reclutamento
- Clinical Trial Site
-
Tlalpan, Messico, 14080
- Reclutamento
- Clinical Trial Site
-
-
-
-
-
Lisbon, Portogallo, 1649-035
- Reclutamento
- Clinical Trial Site
-
Porto, Portogallo, 4099-001
- Reclutamento
- Clinical Trial Site
-
-
-
-
-
London, Regno Unito, NW3 2QG
- Reclutamento
- Clinical Trial Site
-
-
-
-
-
Barcelona, Spagna, 08035
- Reclutamento
- Clinical Trial Site
-
Huelva, Spagna, 21005
- Reclutamento
- Clinical Trial Site
-
L'Hospitalet de Llobregat, Spagna, 8907
- Reclutamento
- Clinical Trial Site
-
Madrid, Spagna, 28040
- Reclutamento
- Clinical Trial Site
-
Palma de Mallorca, Spagna, 07198
- Reclutamento
- Clinical Trial Site
-
-
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- Reclutamento
- Clinical Trial Site
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60611
- Reclutamento
- Clinical Trial Site
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21287
- Reclutamento
- Clinical Trial Site
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02118
- Reclutamento
- Clinical Trial Site
-
-
Minnesota
-
Rochester, Minnesota, Stati Uniti, 55905
- Reclutamento
- Clinical Trial Site
-
-
New York
-
New York, New York, Stati Uniti, 10032
- Reclutamento
- Clinical Trial Site
-
New York, New York, Stati Uniti, 10016
- Reclutamento
- Clinical Trial Site
-
-
North Carolina
-
Chapel Hill, North Carolina, Stati Uniti, 27514
- Reclutamento
- Clinical Trial Site
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37232
- Reclutamento
- Clinical Trial Site
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75246
- Reclutamento
- Clinical Trial Site
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- Clinical Trial Site
-
-
-
-
-
Stockholm, Svezia, 113 61
- Reclutamento
- Clinical Trial Site
-
Umeå, Svezia, 907 37
- Reclutamento
- Clinical Trial Site
-
-
-
-
-
Bern, Svizzera, 3010
- Reclutamento
- Clinical Trial Site
-
-
-
-
-
Taipei, Taiwan, 10002
- Reclutamento
- Clinical Trial Site
-
Taipei, Taiwan, 112
- Reclutamento
- Clinical Trial Site
-
Taoyuan City, Taiwan, 33305
- Reclutamento
- Clinical Trial Site
-
-
-
-
-
Istanbul, Turchia (Türkiye), 34093
- Reclutamento
- Clinical Trial Site
-
Izmir, Turchia (Türkiye), 35330
- Reclutamento
- Clinical Trial Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Has documented diagnosis of hATTR-PN
- Has a diagnosis of hATTR amyloidosis with polyneuropathy with a documented TTR gene variant
- Has a neuropathy impairment score (NIS) of 5 to 130 (inclusive)
- Has a Karnofsky Performance Status (KPS) of ≥60%
Exclusion Criteria:
- Has had a liver transplant or is likely, in the opinion of the Investigator, to undergo liver transplantation during the Treatment Period of the study
- Has known other (non-hATTR) forms of amyloidosis or clinical evidence of leptomeningeal amyloidosis
- Has a New York Heart Association (NYHA) heart failure classification >2
- Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 upper limit of normal (ULN)
- Has total bilirubin >1.5 ULN
- Has estimated glomerular filtration rate (eGFR) ≤30 mL/min/1.73m^2
- Has other known causes of sensorimotor or autonomic neuropathy
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Nucresiran 300 mg
Patients will be administered nucresiran 300 mg subcutaneously (SC) once every 6 months (q6M) during the Treatment Period and Treatment Extension Period |
Nucresiran 300 mg administered SC q6M
Altri nomi:
|
|
Comparatore attivo: Vutrisiran 25 mg followed by Nucresiran 300 mg
Patients will be administered vutrisiran 25 mg SC every 3 months (q3M) during the Treatment Period followed by nucresiran 300 mg SC q6M during the Treatment Extension Period |
Nucresiran 300 mg administered SC q6M
Altri nomi:
Vutrisiran 25 mg administered SC q3M
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change from Baseline in the Modified Neuropathy Impairment Score +7 (mNIS+7) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
Lasso di tempo: Baseline and Month 9
|
The mNIS+7 is a composite score that measures neurologic impairment which includes the following components: physical exam of lower limbs, upper limbs and cranial nerves to assess motor strength/weakness and deep tendon reflexes, electrophysiologic measurement of large nerve fiber function, sensory testing and postural blood pressure. The mNIS+7 is scored from 0 (no impairment) to 304 points (maximum impairment). A higher score indicates a worse outcome. |
Baseline and Month 9
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentuale di Riduzione dei Livelli Sierici di TTR nel Gruppo Nucresiran Rispetto al Gruppo Vutrisiran in Studio fino al Mese 9
Lasso di tempo: Fino al Mese 9
|
Fino al Mese 9
|
|
|
Riduzione Percentuale dei Livelli Sierici di TTR nel Gruppo Nucresiran Rispetto al Gruppo Vutrisiran in Studio fino al Mese 18
Lasso di tempo: Fino al Mese 18
|
Fino al Mese 18
|
|
|
Percentuale di Riduzione dei Livelli di Siero TTR nel Gruppo Nucresiran Rispetto al Gruppo Vutrisiran in Studio alla Settimana 6
Lasso di tempo: Settimana 6
|
Settimana 6
|
|
|
Change from Baseline in Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) Total Score Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
Lasso di tempo: Baseline and Month 9
|
The Norfolk QoL-DN is a standardized 35-item patient-rated questionnaire used to assess 5 domains: physical function, large fiber neuropathy, activities of daily living, symptoms, small fiber neuropathy, and autonomic neuropathy. The minimum and maximum values are -4 and 136, respectively. A higher score indicates a worse outcome. |
Baseline and Month 9
|
|
Change from Baseline in Modified Body Mass Index (mBMI) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
Lasso di tempo: Baseline and Month 9
|
The mBMI, which is a measure of nutritional status, is calculated as the product of body mass index (BMI) (weight in kilograms divided by the square of height in meters) and serum albumin (g/L) to reflect fluid balance, such as fluid accumulation or dehydration. A negative change from baseline indicates a better outcome. |
Baseline and Month 9
|
|
Change from Baseline in the mNIS+7 Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Lasso di tempo: Baseline and Month 18
|
The mNIS+7 is a composite score that measures neurologic impairment which includes the following components: physical exam of lower limbs, upper limbs and cranial nerves to assess motor strength/weakness and deep tendon reflexes, electrophysiologic measurement of large nerve fiber function, sensory testing and postural blood pressure. The mNIS+7 is scored from 0 (no impairment) to 304 points (maximum impairment). A higher score indicates a worse outcome. |
Baseline and Month 18
|
|
Change from Baseline in Norfolk QoL-DN Total Score Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Lasso di tempo: Baseline and Month 18
|
The Norfolk QoL-DN is a standardized 35-item patient-rated questionnaire used to assess 5 domains: physical function, large fiber neuropathy, activities of daily living, symptoms, small fiber neuropathy, and autonomic neuropathy. The minimum and maximum values are -4 and 136, respectively. A higher score indicates a worse outcome. |
Baseline and Month 18
|
|
Change from Baseline in mBMI Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Lasso di tempo: Baseline and Month 18
|
The mBMI, which is a measure of nutritional status, is calculated as the product of body mass index (BMI) (weight in kilograms divided by the square of height in meters) and serum albumin (g/L) to reflect fluid balance, such as fluid accumulation or dehydration. A negative change from baseline indicates a better outcome. |
Baseline and Month 18
|
|
Change from Baseline in Rasch-built Overall Disability Scale (R-ODS) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Lasso di tempo: Baseline and Month 18
|
The R-ODS is a patient-reported measure of level of disability on a scale of 0-48, with 0 being the worst and 48 the best (no limitations); scores are based on activities of daily living and social participation. An increase in R-ODS from baseline suggests improvement in disability, and a decrease from baseline suggests worsening of disability. |
Baseline and Month 18
|
|
Change from Baseline in Timed 10-meter Walk Test (10-MWT) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Lasso di tempo: Baseline and Month 18
|
The timed 10-MWT is a measure of ambulatory ability and measures the time (in seconds) that it takes a participant to walk 10 meters (gait speed). An increase in gait speed from baseline represents improvement, and a decrease from baseline represents worsening. |
Baseline and Month 18
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Medical Director, Alnylam Pharmaceuticals
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- ALN-TTRSC04-004
- 2025-522544-40-00 (Ctis)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Phase 2-4 trials:
Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the US and/or the EU.
Access to data may be declined where there is likelihood a patient could be identified or other feasibility issue, where there is a potential conflict of interest, a planned business activities or an actual or potential competitive risk. Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Timeframes for data access may vary and can take up to 6 months or more.
Requests for access to data can be submitted via the website www.vivli.org. Questions can also be directed to datasharing@alnylam.com.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .